2.5 Hemostasis & Primary Coagulation

Hemostasis & Primary Coagulation

Quick Answer: Hemostasis is the body's mechanism to stop bleeding. Primary hemostasis is the initial, rapid response involving blood vessel constriction and platelets rushing in to form a temporary plug at the site of injury. Without this plug, the secondary coagulation cascade has no scaffold to build upon.

Overview of Hemostasis

Hemostasis must strike a delicate balance: preventing excessive exsanguination (bleeding) while avoiding inappropriate thrombosis (clotting that occludes vessels). The physiologic process is traditionally divided into three interconnected phases:

1. Primary Hemostasis: The interaction between the blood vessel wall and platelets to rapidly form a primary, unstable platelet plug.
2. Secondary Hemostasis: The enzymatic coagulation cascade, which generates a stable fibrin mesh to reinforce and solidify the platelet plug.
3. Fibrinolysis: The eventual enzymatic breakdown and removal of the fibrin clot as the underlying vascular tissue heals.

Mechanisms of Primary Hemostasis

When the endothelial lining of a blood vessel is damaged, the subendothelial collagen matrix is exposed to flowing blood. This triggers a rapid sequence of events:

1. Vascular Spasm (Vasoconstriction)

The injured vessel immediately contracts to reduce blood flow and limit blood loss. This is mediated by neurogenic reflexes and localized secretion of endothelin and thromboxane A2.

2. Platelet Adhesion

Platelets flowing in the high-shear environment of the blood must stick to the exposed subendothelial collagen. They cannot do this directly.

• This adhesion process absolutely requires von Willebrand Factor (vWF), a large multimeric protein secreted by endothelial cells (stored in Weibel-Palade bodies) and platelets.
• vWF acts as molecular glue. It binds to the exposed collagen on one side, and binds to the Glycoprotein Ib (GpIb) receptor on the platelet surface on the other side, tethering the platelet to the injury site.

3. Platelet Activation & Secretion (Release Reaction)

Once adhered, the platelet undergoes a profound metabolic and morphological transformation. It changes shape from a smooth disc to a spiny sphere with pseudopods, maximizing its surface area. The platelet then degranulates, releasing the contents of its intracellular granules into the microenvironment to recruit more platelets:

• Dense Granules: Release ADP (a potent platelet activator), ATP, Serotonin (promotes vasoconstriction), and Calcium.
• Alpha Granules: Release additional vWF, Fibrinogen, Platelet Factor 4, and Factor V. Simultaneously, the platelet membrane synthesizes Thromboxane A2 (TXA2) via the cyclooxygenase (COX-1) pathway, which promotes intense further activation and vasoconstriction.

4. Platelet Aggregation

Activated platelets stick to one another to form the expanding platelet plug.

• This requires a conformational change in the Glycoprotein IIb/IIIa (GpIIb/IIIa) receptor on the platelet surface, rendering it active.
• Fibrinogen (from the plasma and alpha granules) acts as the bridge, connecting adjacent platelets by binding to the GpIIb/IIIa receptors on both cells.

Disorders of Primary Hemostasis

Defects in primary hemostasis generally present clinically with mucocutaneous bleeding patterns: petechiae (pinpoint hemorrhages), purpura, epistaxis (nosebleeds), gingival bleeding, and menorrhagia. Deep tissue bleeds and hemarthroses are not typical (those indicate secondary hemostasis defects like Hemophilia).

Quantitative Disorders (Thrombocytopenia)

A low platelet count (<150,000/μL). Can be due to decreased bone marrow production (aplastic anemia, leukemia), increased peripheral destruction (Immune Thrombocytopenic Purpura - ITP, Thrombotic Thrombocytopenic Purpura - TTP), or splenic sequestration.

Qualitative Disorders (Platelet Function Defects)

The platelet count is normal, but the platelets are biochemically incapable of functioning correctly.

Platelet Aggregation Studies (Light Transmission Aggregometry)

This is the gold standard for diagnosing qualitative platelet defects. Platelet-rich plasma (PRP) is placed in an aggregometer, and a light beam shines through it. As chemical agonists are added and platelets clump together, more light transmits through the plasma, generating an aggregation curve.

Standard agonists include ADP, Epinephrine, Collagen, and Ristocetin.

• Normal Response: Addition of ADP, Epinephrine, and Collagen induces full primary and secondary waves of aggregation. Addition of Ristocetin (which forces vWF to bind to GpIb) causes agglutination.
• Glanzmann Thrombasthenia: Platelets fail to aggregate with ADP, Epinephrine, and Collagen (flat lines). However, they will agglutinate normally with Ristocetin (because GpIb and vWF are normal).
• Bernard-Soulier Syndrome: Platelets aggregate normally with ADP, Epinephrine, and Collagen. However, they fail to agglutinate with Ristocetin (because the GpIb receptor is missing). The addition of normal plasma (which contains vWF) does not correct the ristocetin curve.
• von Willebrand Disease (vWD): Similar to Bernard-Soulier, platelets fail to agglutinate with Ristocetin (because vWF is missing). However, unlike Bernard-Soulier, adding normal plasma (replacing the missing vWF) corrects the ristocetin curve.